RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.
High-dimensional single-cell proteomics analysis of esophageal squamous cell carcinoma reveals dynamic alterations of the tumor immune microenvironment after neoadjuvant therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本研究揭示新辅助治疗显著调控 ESCC 肿瘤免疫微环境的细胞组成,并提出 CCR4/CCR6 系统潜在模型以预测新辅助放化疗联合免疫治疗的获益。
不同新辅助治疗后,食管鳞状细胞癌(ESCC)肿瘤免疫微环境的动态变化研究不足。
我们对6份邻近正常食管黏膜及26份ESCC肿瘤样本(未经治疗n=12,新辅助治疗后n=14)使用包含42种抗体的质谱流式面板进行分析。研究还分析了既往研究的单细胞RNA测序数据及癌症基因组图谱(TCGA)散装RNA测序数据,并开展流式细胞术、免疫组化及免疫荧光分析。
新辅助化疗组肿瘤退缩较差。放疗为基础的方案增加CD8+ T细胞、减少调节性T细胞,并提高效应记忆T细胞与中央记忆T细胞的比例。免疫检查点阻断通过提高CD16+ NK细胞比例,增强NK细胞活化和细胞毒性。我们发现一种新型CCR4+CCR6+巨噬细胞亚群,其与相应趋化因子CCL3、CCL5、CCL17、CCL20和CCL22富集相关。我们据CCR4/CCR6趋化因子建立模型,可对总体生存和新辅助放化疗联合免疫治疗应答不同的ESCC患者进行分层,并在两个独立的新辅助治疗食管癌队列中得到验证。
本研究揭示新辅助治疗可显著调节ESCC肿瘤免疫微环境中的细胞组成,并提出潜在的CCR4/CCR6系统模型,用于预测新辅助放化疗联合免疫治疗的获益。
Dynamic alterations of the tumor immune microenvironment in esophageal squamous cell carcinoma (ESCC) after different neoadjuvant therapies were understudied.
We used mass cytometry with a 42-antibody panel for 6 adjacent normal esophageal mucosa and 26 tumor samples (treatment-na ve, n=12; postneoadjuvant, n=14) from patients with ESCC. Single-cell RNA sequencing of previous studies and bulk RNA sequencing from The Cancer Genome Atlas were analyzed, flow cytometry, immunohistochemistry, and immunofluorescence analyses were performed.
Poor tumor regression was observed in the neoadjuvant chemotherapy group. Radiotherapy-based regimens enhanced CD8 + T cells but diminished regulatory T cells and promoted the ratio of effector memory to central memory T cells. Immune checkpoint blockade augmented NK cell activation and cytotoxicity by increasing the frequency of CD16 + NK cells. We discovered a novel CCR4 + CCR6 + macrophage subset that correlated with the enrichment of corresponding chemokines (CCL3/CCL5/CCL17/CCL20/CCL22). We established a CCR4/CCR6 chemokine-based model that stratified ESCC patients with differential overall survival and responsiveness to neoadjuvant chemoradiotherapy combined with immunotherapy, which was validated in two independent cohorts of esophageal cancer with neoadjuvant treatment.
This work reveals that neoadjuvant therapy significantly regulates the cellular composition of the tumor immune microenvironment in ESCC and proposes a potential model of CCR4/CCR6 system to predict the benefits from neoadjuvant chemoradiotherapy combined with immunotherapy.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。